Kura Oncology (NASDAQ:KURA) Stock: Insider Troy Edward Wilson Buys 98,881 Shares

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) CEO Troy Wilson acquired 98,881 shares of Kura Oncology stock in a transaction on Friday, November 13th. The shares were bought at an average cost of $7.63 per share, for a total transaction of $754,462.03. Following the completion of the purchase, the chief executive officer directly owned 534,337 shares of the company’s stock, valued at $4,076,991.31. The trade was a 22.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Troy Edward Wilson also recently made the following trade(s):

  • On Monday, November 16th, Troy Wilson acquired 101,119 shares of Kura Oncology stock. The shares were bought at an average price of $7.42 per share, for a total transaction of $750,302.98.
  • On Monday, August 24th, Troy Wilson acquired 100,000 shares of Kura Oncology stock. The stock was bought at an average cost of $12.39 per share, with a total value of $1,239,000.00.

Kura Oncology Trading Down 8.8%

Shares of NASDAQ:KURA traded down $0.68 during trading on Monday, hitting $7.09. The company had a trading volume of 2,621,535 shares, compared to its average volume of 2,345,466. Kura Oncology, Inc. has a one year low of $6.75 and a one year high of $13.90. The company has a fifty day simple moving average of $10.05 and a two-hundred day simple moving average of $9.76. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.60 and a quick ratio of 4.71.

Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.04. The firm had revenue of $22.84 million during the quarter, compared to analysts’ expectations of $24.94 million. Kura Oncology had a negative return on equity of 336.24% and a negative net margin of 369.26%. Equities research analysts anticipate that Kura Oncology, Inc. will post -3.20 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $115,286,000. Bank of America Corp DE purchased a new position in Kura Oncology during the 2nd quarter valued at $12,735,000. Dimensional Fund Advisors LP grew its position in Kura Oncology by 32.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after acquiring an additional 348,127 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Kura Oncology in the 2nd quarter valued at $10,927,000. Finally, Aberdeen Group plc bought a new position in Kura Oncology in the 3rd quarter valued at $8,443,000.

Wall Street Analysts Forecast Growth

Several research analysts have commented on KURA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, October 15th. Deutsche Bank set a $24.00 price objective on shares of Kura Oncology in a research report on Wednesday, October 14th. Raymond James Financial set a $24.00 target price on shares of Kura Oncology in a research note on Monday, August 24th. Citizens Jmp restated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a report on Monday, August 24th. Finally, Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a research note on Monday, August 24th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and an average target price of $25.88.

Get Our Latest Stock Analysis on KURA

About Kura Oncology

(Get Free Report)

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.

Featured Articles

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.